TOVX
$0.19+0.01 (+4.36%)
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
Recent News
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design
Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency on the design of a Phase 3 clinical trial of lead clinical candidate VCN-01 in combination with gemcitabine/nab-paclitaxel standard-of-care chemotherapy for the first-line treatment of metastatic PDAC. The Company has previously reported the results of the VIRAGE randomized, controlled Phase 2b clinical trial, demonstrating that PDAC patient
Theriva Biologics: Q3 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Wednesday reported a loss of $4.4 million in its third quarter.
Theriva Biologics: Q2 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Monday reported a loss of $13.1 million in its second quarter.
Theriva Biologics: Q1 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Wednesday reported a loss of $4.3 million in its first quarter.